Genprex 10-Q: Focus on Future Funding Amidst Operating Losses
Ticker: GNPX · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 1595248
Sentiment: neutral
Topics: biotech, 10-Q, financials, pharmaceuticals
Related Tickers: GNPX
TL;DR
Genprex 10-Q shows $5.49M assets, minimal revenue, big losses. Still betting on future funding.
AI Summary
Genprex, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue and significant operating losses, consistent with its stage of development in the pharmaceutical sector. Key financial figures include total assets of $5.49 million and a substantial authorized share capital, indicating a focus on future funding and growth.
Why It Matters
This filing provides insight into Genprex's financial health and operational status as it advances its pharmaceutical development, which is crucial for investors and stakeholders to assess the company's viability and potential.
Risk Assessment
Risk Level: high — The company operates in the highly speculative pharmaceutical development sector with significant operating losses and reliance on future funding.
Key Numbers
- $5.49B — Total Assets (As of September 30, 2024, indicating the company's resource base.)
- 200,000,000 — Authorized Shares (Reflects the company's capital structure and potential for future equity financing.)
- 0.001 — Revenue (Minimal reported revenue for the period, typical for early-stage biotech.)
Key Players & Entities
- Genprex, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- $5,489,152 (dollar_amount) — Total assets as of September 30, 2024
- 200,000,000 (dollar_amount) — Authorized shares
FAQ
What were Genprex's total revenues for the nine months ended September 30, 2024?
The filing indicates minimal revenue, with a value of $0.001 for the period.
What is the total amount of assets reported by Genprex as of September 30, 2024?
Genprex reported total assets of $5,489,152 as of September 30, 2024.
How many shares of common stock is Genprex authorized to issue?
Genprex has authorized 200,000,000 shares of common stock.
What is the company's fiscal year end?
Genprex's fiscal year ends on December 31.
What is the filing date of this 10-Q report?
This 10-Q report was filed on November 13, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on November 13, 2024 regarding Genprex, Inc. (GNPX).